Overview of Imatin
| Property | Description |
|---|---|
| Active Ingredient | Imatinib mesylate |
| Form | Oral tablet or solution |
| Pharmacological Class | Tyrosine Kinase Inhibitor (TKI), Antineoplastic agent |
| Common Use | Managing abnormal cell growth |
| Origin | Synthetic, small molecule inhibitor |
Defining Imatin: Composition and Type
Imatin is a prescription-only medication whose active pharmaceutical ingredient is Imatinib mesylate, a synthesized small molecule compound. It is primarily classified as an antineoplastic agent within the broader field of oncology. The drug is a single-ingredient product typically provided for the oral route of administration in the form of a tablet or an oral solution. As a version of the originator compound, Imatin possesses high oral bioavailability, which is recognized for facilitating long-term patient adherence.
What Type of Therapy is Imatin?
Imatin is specifically categorized as a Protein Kinase Inhibitor, functioning as a Tyrosine Kinase Inhibitor (TKI). This classification signifies that Imatinib is a form of targeted therapy, a departure from older, conventional cytotoxic chemotherapy agents. The development of imatinib is characterized as establishing the therapeutic category known as targeted therapy. This advanced therapeutic approach uses the synthetic compound, a 2-phenylamino-pyrimidine derivative, to focus its action on underlying molecular causes, distinguishing it from general cell-killing treatments.
The General Purpose of Imatinib
The general purpose of Imatinib is to help manage medical conditions driven by the abnormal, uncontrolled growth of specific cells. It achieves this by performing a signal transduction inhibition, which means it blocks hyperactive growth signals within cells that tell them to multiply. Imatinib is designed to neutralize specific malignant proteins, such as the BCR-ABL fusion protein, along with other related signaling proteins like c-Kit (KIT) and the Platelet-Derived Growth Factor Receptor (PDGFR). It acts as a selective inhibitor of these various protein tyrosine kinases. By disrupting these continuous growth messages, Imatinib leads to the selective self-destruction (apoptosis) of the unhealthy cells.
Regulatory References
